Develop Cannabis sativa strains for pets. Target the European Union market. Now — the numbers.
There is not enough trading history here to call this an established business.
Red columns mark years that ended in a loss.
The gap is $311.09. In times of high interest rates, a gap like that can squeeze a company.
The market pays 1,158.6× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
The stock sits at $0.0060. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 5 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.